Movers and SHAKERS
Onconova Therapeutics Inc. (ONTX)
Phase 1 Trial Commencement for CDK4/6 ARK5 Program in H1 2021, Rating Raised
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.
Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
The trial is expected to commence in H1 2021. Onconova’s dual CDK4/6 and ARK5 inhibitor ON 123300 is set to enter the clinic in H1 2021 following the Investigational New Drug (IND) filing approval announced yesterday. CDK4/6 coupled with ARK5 inhibition is a unique and innovative approach and potentially represents an effective strategy to treat patients who are resistant or refractory to CDK4/6 therapeutics.
Details of Phase 1 study and the potential market opportunity. The Phase 1 study will assess the safety, tolerability, and pharmacokinetics of ON 123300 administered orally as monotherapy at increasing doses starting at 40 mg daily for consecutive 28-day cycles. The target population includes but is not limited to HR+ HER2- metastatic breast cancer patients with clinical resistance to approved ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.